Once hailed as a “gold standard” treatment for women after childbirth, vaginal mesh implants have become one of the biggest medical scandals ...

ON THIS PAGEWhy Urgency Happens in UCSolutions for UC UrgencyWhen Urgency Is a Bigger ProblemMore than80 percent of people with ulcerative colitis (UC) experience bowel urgency that overwhelming, need ...

Millions live with incontinence—and pay the price. NAFC’s We Count campaign spotlights the often-overlooked financial ...

Cosmetic nurse to celebrities Alex Pike told Daily Mail that while she doesn't personally offer the treatment, she's noticed a huge uptick in women asking about it in the last six months.

An automated urinary incontinence screening and education program increased awareness, diagnosis, and treatment of the condition. After the program was implemented, rates of physical therapy and ...

Kate Hickey was at a trampoline park with her children when she felt pressure in her pelvic area and knew something was wrong ...

Chanelle Surginer had a family, a career and a home when trauma derailed her, resulting in substance abuse. She lost her job, custody of her children and her house. Within three months she lost ...

Women in this facility endure dehumanizing procedures that contradict every value espoused in the Governor’s river of hope-filled sentiments. It is the height of irony. In the same month officially ...

Scientists looking to provide relief for people with inflammatory bowel disease have turned to an unusual source for inspiration: barnacles. Inflammatory bowel disease (IBD), such as Crohn’s disease ...

What Is Addyi, and Why Does It Matter? Addyi (flibanserin) is a nonhormonal prescription pill that is now approved by the FDA to treat low sexual desire in women younger than 65, including those who ...

New research indicates that a long-maligned menopausal treatment is safer than previously thought, showing that it doesn’t increase breast cancer risk in women with inherited mutations in the BRCA1 or ...

HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company’s lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory ...